Prognostic Impact of Sarcomatoid Component Proportion in Grade 4 Non-Metastatic ccRCC
Overview
This study evaluated the prognostic significance of the percentage of sarcomatoid component in grade 4 non-metastatic clear cell renal cell carcinoma (ccRCC). A cutoff of 20% sarcomatoid component distinguished patients with worse cancer-specific survival and recurrence-free survival. High sarcomatoid proportion correlated with larger tumor size and advanced stage.
Background
Renal cell carcinoma (RCC) is a common malignancy worldwide, with clear cell RCC (ccRCC) being the most frequent histotype. The 2022 WHO/ISUP grading system classifies ccRCC into four grades based on nuclear features, with grade 4 characterized by extreme pleomorphism and presence of sarcomatoid or rhabdoid components. Sarcomatoid dedifferentiation indicates a highly aggressive tumor phenotype associated with poor prognosis. However, the prognostic impact of the proportion of sarcomatoid component within tumors has been insufficiently studied.
Data Highlights
Parameter
Low Sarcomatoid (<20%)
High Sarcomatoid (≥20%)
P-value
Number of patients
95 (44.8%)
117 (55.2%)
Median tumor size
Smaller
Larger
0.001
Radical nephrectomy
86.8% overall
86.8% overall
ROC AUC for CSS
0.61 (95% CI 0.53–0.67)
0.006
ROC AUC for RFS
0.60 (95% CI 0.51–0.69)
0.01
Key Findings
A sarcomatoid component cutoff of 20% optimally stratifies patients for cancer-specific survival (CSS) and recurrence-free survival (RFS).
Patients with ≥20% sarcomatoid component (high sarcomatoid) had significantly larger tumors compared to those with <20% (low sarcomatoid).
High sarcomatoid proportion is associated with more advanced tumor stage at diagnosis.
The presence of any sarcomatoid component defines grade 4 ccRCC, but the extent of sarcomatoid differentiation further refines prognosis.
Multivariable Cox regression identified sarcomatoid percentage as an independent predictor of CSS and RFS.
Clinical Implications
Assessment of the percentage of sarcomatoid component in grade 4 ccRCC provides valuable prognostic information beyond the binary presence of sarcomatoid features. Patients with ≥20% sarcomatoid differentiation represent a higher-risk group that may benefit from closer surveillance and potentially more aggressive adjuvant therapies. Accurate quantification of sarcomatoid areas using digital pathology tools can aid in risk stratification and treatment planning.
Conclusion
The proportion of sarcomatoid component in grade 4 non-metastatic ccRCC is a significant prognostic factor, with ≥20% sarcomatoid differentiation indicating worse outcomes. Incorporating sarcomatoid percentage into pathological assessment enhances prognostic accuracy and may guide clinical management.
References
American Cancer Society 2024 -- Kidney Cancer Statistics
WHO/ISUP 2022 -- Grading System for Renal Cell Carcinoma
Sarcomatoid RCC Prognosis Studies -- Various Authors
by Giuseppe Lucarelli, Francesco Lasorsa, Monica Rutigliano, Martina Milella, Marco Spilotros, Antonio d’Amati, Giuseppe Ingravallo, Felice Crocetto, Savio Domenico Pandolfo, Marco Fabiano, Matteo Ferro, Riccardo Autorino, Michele Battaglia, Pasquale Ditonno
